Lyell Immunopharma Inc

NASDAQ:LYEL   3:59:56 PM EDT
5.15
-0.29 (-5.33%)
Products, Strategic Combinations

Lyell Immunopharma Says Entered Into Second Amendment To Collaboration And License Agreement With GSK

Published: 12/17/2021 22:01 GMT
Lyell Immunopharma Inc (LYEL) - Lyell Immunopharma - on Dec 16, Co Entered Into Second Amendment to Collaboration and License Agreement With Gsk.
Lyell Immunopharma - Under Amendment, to Manufacture Ny-eso-1 + Epi-r Tcr Cell Therapy Product Candidate for Epi-r Trial at Bothell Facility.
Lyell Immunopharma - Collaboration Amendment Specifies That Lyell Owns Improvements to the Epi-r and Gen-r Technologies.
Lyell Immunopharma -under Amendment, Eligible to Receive Milestone Payments for Any Use of Anti-exhaustion Component Related to a Collaboration Target.
Further Company Coverage: Lyelo ((reuters.
Briefs@thomsonreuters.
Com;)).